株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

拡張型心筋症 : パイプライン分析

Dilated Cardiomyopathy - Pipeline Review, H2 2019

発行 Global Markets Direct 商品コード 246011
出版日 ページ情報 英文 55 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.62円で換算しております。
Back to Top
拡張型心筋症 : パイプライン分析 Dilated Cardiomyopathy - Pipeline Review, H2 2019
出版日: 2019年08月30日 ページ情報: 英文 55 Pages
概要

拡張型心筋症(DCM)とは、左心室の拡張・衰弱により、心臓が血液を送り出す機能が低下する状態のことを指します。場合によっては、心臓を緩めて血液を十分に取り込むことが出来なくなります。時間が経つにつれ、心臓の他の心室にも影響が及んできます。

当レポートでは、世界各国での拡張型心筋症治療用のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要(製品概要、機能メカニズム、研究開発(R&D)の進展状況)、最新の業界動向などを調査して、その結果をお届けします。

イントロダクション

  • 分析範囲

拡張型心筋症の概要

治療薬の開発

  • 拡張型心筋症向けパイプライン製品:概要
  • 拡張型心筋症向けパイプライン製品:比較分析

各企業で開発中の拡張型心筋症治療薬

大学/研究機関で研究中の拡張型心筋症治療薬

パイプライン製品の概略

  • 治験段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

拡張型心筋症治療薬:開発中の製品の一覧(企業別)

拡張型心筋症治療薬:研究中の製品の一覧(大学/研究機関別)

拡張型心筋症治療薬の開発に従事している企業

  • Array BioPharma Inc.
  • Hemostemix Ltd
  • Kasiak Research Private Limited
  • Sanofi
  • Vericel Corporation

拡張型心筋症:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 機能メカニズム別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • ACP-01
  • ARRY-797
  • CAP-1002
  • 拡張型心筋症向け薬剤
  • ixmyelocel-T
  • Refacell-DCM
  • 拡張型心筋症向け小分子

拡張型心筋症治療薬:最新の薬剤プロファイル

拡張型心筋症治療薬:開発が休止状態の製品

拡張型心筋症関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

図表

List of Tables

  • Number of Products under Development for Dilated Cardiomyopathy, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Dilated Cardiomyopathy - Pipeline by Berlin Cures Holding AG, H2 2019
  • Dilated Cardiomyopathy - Pipeline by Celixir Ltd, H2 2019
  • Dilated Cardiomyopathy - Pipeline by Martin Pharmaceuticals Inc, H2 2019
  • Dilated Cardiomyopathy - Pipeline by MyoKardia Inc, H2 2019
  • Dilated Cardiomyopathy - Pipeline by Pfizer Inc, H2 2019
  • Dilated Cardiomyopathy - Pipeline by Shionogi & Co Ltd, H2 2019
  • Dilated Cardiomyopathy - Dormant Projects, H2 2019

List of Figures

  • Number of Products under Development for Dilated Cardiomyopathy, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products by Targets, H2 2019
  • Number of Products by Stage and Targets, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
目次
Product Code: GMDHC11359IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dilated Cardiomyopathy - Pipeline Review, H2 2019, provides an overview of the Dilated Cardiomyopathy (Cardiovascular) pipeline landscape.

Dilated cardiomyopathy (DCM) is a condition in which the heart's ability to pump blood is decreased because the heart's main pumping chamber, the left ventricle, is enlarged and weakened. Symptoms include Fatigue and weakness, Shortness of breath (dyspnea), lightheadedness, dizziness or fainting, persistent cough or wheezing, lack of appetite, sudden weight gain from fluid retention and swelling (edema) in legs, ankles and feet. Risk factors include family history, alcoholism, hypertension, cocaine abuse and metabolic disorders, such as thyroid disease or diabetes.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dilated Cardiomyopathy - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Dilated Cardiomyopathy (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dilated Cardiomyopathy (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Dilated Cardiomyopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Dilated Cardiomyopathy (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Dilated Cardiomyopathy (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Dilated Cardiomyopathy (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Dilated Cardiomyopathy (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Dilated Cardiomyopathy (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Dilated Cardiomyopathy (Cardiovascular)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Dilated Cardiomyopathy (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Dilated Cardiomyopathy (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Dilated Cardiomyopathy - Overview
  • Dilated Cardiomyopathy - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Dilated Cardiomyopathy - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Dilated Cardiomyopathy - Companies Involved in Therapeutics Development
    • Berlin Cures Holding AG
    • Celixir Ltd
    • Martin Pharmaceuticals Inc
    • MyoKardia Inc
    • Pfizer Inc
    • Shionogi & Co Ltd
  • Dilated Cardiomyopathy - Drug Profiles
    • ARRY-797 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BC-007 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate BAG3 for Dilated Cardiomyopathy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Heartcel - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HS-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-005151 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SAR-440181 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Dilated Cardiomyopathy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Myocardial Infarction and Dilated Cardiomyopathy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • trimetazidine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • YS-1402 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Dilated Cardiomyopathy - Dormant Projects
  • Dilated Cardiomyopathy - Product Development Milestones
    • Featured News & Press Releases
      • May 30, 2019: MyoKardia's MYK-491 shows favourable profile in Phase Ia study
      • Apr 15, 2019: Berlin Cures announces start of Phase IIa for its DNA-based neutralizer of B1-adrenoceptor autoantibodies
      • Dec 11, 2018: MyoKardia reports positive data from phase 1b single-ascending dose clinical trial of MYK-491 in dilated cardiomyopathy and systolic heart failure patients
      • Dec 06, 2018: Berlin Cures steering committee is assembled to facilitate the design and implementation of phase 2 study of BC 007
      • Oct 30, 2018: MyoKardia Shares Data from new research program ACT-1 at 2018 R&D Day
      • Feb 26, 2018: Heart Failure Treatment from Berlin Cures Shows Promise in Phase 1 Study
      • Feb 14, 2018: MyoKardia Begins Patient Dosing in Phase 1b Clinical Study of MYK-491 in Dilated Cardiomyopathy Patients
      • Nov 02, 2017: MyoKardia Provides Update on MYK-491
      • Sep 27, 2017: MyoKardia Provides Update on MYK-491 Clinical Progress
      • Feb 02, 2017: First Subjects Dosed in MyoKardia Phase 1 Study of Dilated Cardiomyopathy Candidate MYK-491
      • Dec 02, 2016: MyoKardia Announces Receipt of Milestone Payment from Sanofi for DCM Candidate MYK-491
      • Aug 30, 2016: Array Presents Data from Cardiovascular Trial with ARRY-797 at the European Society of Cardiology Congress
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top